CLU was found to be expressed at a lower level in the high-risk C3 subtype of prostate cancer, with significantly less infiltration of CD8 T cells, monocytes, resting dendritic cells, activated dendritic cells, and activated mast cells, implying that CLU may influence immune cell infiltration through some mechanism (Zhang et al., 2020). Here, CD8A is linked to prostate cancer.